Representative Jefferson Shreve (R-Indiana) recently sold shares of Zoetis Inc. NYSE: ZTS. In a filing disclosed on June 22nd, the Representative disclosed that they had sold between $15,001 and $50,000 in Zoetis stock on May 12th. The trade occurred in the Representative's "CRT - STANDARD UNIT TRUST" account.
Representative Jefferson Shreve also recently made the following trade(s):
- Sold $15,001 - $50,000 in shares of Hubbell NYSE: HUBB on 5/12/2025.
- Sold $50,001 - $100,000 in shares of Trane Technologies NYSE: TT on 5/12/2025.
- Sold $15,001 - $50,000 in shares of RTX NYSE: RTX on 5/12/2025.
- Sold $50,001 - $100,000 in shares of NiSource NYSE: NI on 5/12/2025.
- Sold $50,001 - $100,000 in shares of Johnson & Johnson NYSE: JNJ on 5/12/2025.
- Sold $15,001 - $50,000 in shares of AppLovin NASDAQ: APP on 5/12/2025.
- Sold $15,001 - $50,000 in shares of Fiserv NYSE: FI on 5/12/2025.
- Sold $15,001 - $50,000 in shares of CNO Financial Group NYSE: CNO on 5/12/2025.
- Sold $50,001 - $100,000 in shares of Cboe Global Markets NASDAQ: CBOE on 5/12/2025.
- Sold $15,001 - $50,000 in shares of Lam Research NASDAQ: LRCX on 5/12/2025.
Zoetis Price Performance
ZTS traded down $0.90 during trading on Friday, reaching $151.92. The stock had a trading volume of 3,326,080 shares, compared to its average volume of 2,967,721. The stock has a market cap of $67.64 billion, a PE ratio of 27.28, a PEG ratio of 2.53 and a beta of 0.91. The company has a debt-to-equity ratio of 1.12, a quick ratio of 1.04 and a current ratio of 1.74. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33. The business has a 50-day moving average of $159.91 and a 200-day moving average of $161.01.
Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. The business had revenue of $2.22 billion for the quarter, compared to analysts' expectations of $2.20 billion. Zoetis had a return on equity of 55.48% and a net margin of 27.12%. The firm's revenue was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.38 earnings per share. As a group, equities research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.
Zoetis Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be paid a $0.50 dividend. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 dividend on an annualized basis and a yield of 1.32%. Zoetis's dividend payout ratio is presently 35.91%.
Analyst Upgrades and Downgrades
A number of research analysts have recently issued reports on ZTS shares. UBS Group reduced their price objective on Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. Piper Sandler raised their price objective on Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a research note on Monday, May 12th. Leerink Partnrs cut Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and reduced their price objective for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Finally, Leerink Partners cut Zoetis from an "outperform" rating to a "market perform" rating and reduced their price objective for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Zoetis currently has an average rating of "Moderate Buy" and a consensus price target of $204.63.
Read Our Latest Report on Zoetis
Insider Activity
In other news, EVP Roxanne Lagano sold 652 shares of the business's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total transaction of $110,840.00. Following the completion of the sale, the executive vice president owned 15,129 shares of the company's stock, valued at $2,571,930. The trade was a 4.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.18% of the stock is currently owned by insiders.
Institutional Trading of Zoetis
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Nova Wealth Management Inc. purchased a new position in shares of Zoetis during the first quarter valued at approximately $25,000. 1248 Management LLC bought a new stake in Zoetis in the 1st quarter worth approximately $27,000. Rakuten Securities Inc. grew its position in Zoetis by 5,533.3% in the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock worth $28,000 after purchasing an additional 166 shares during the period. Saudi Central Bank bought a new stake in Zoetis in the 1st quarter worth approximately $29,000. Finally, Navigoe LLC bought a new stake in shares of Zoetis during the 4th quarter valued at $30,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.
About Representative Shreve
Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana's 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana's 6th Congressional District. He declared candidacy for the 2026 election.
Email editor@ballotpedia.org to notify us of updates to this biography.
Jefferson Shreve earned a bachelor's degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve's career experience includes working as a real estate executive.
Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.
Zoetis Company Profile
(
Get Free Report)
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Further Reading
Before you consider Zoetis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.
While Zoetis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
